CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
OC-02 (simpinicline) nasal spray +1 moredrug
Likely dose
OC-02 (simpinicline) nasal spray 11.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03633461
NCT03633461Phase 2Completed
CompareCT.gov

Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

Oyster Point Pharma, Inc.·interventional·Posted Aug 16, 2018·Updated Mar 9, 2022

In Brief

A Phase 2 clinical trial evaluating OC-02 (simpinicline) nasal spray and Placebo (vehicle) nasal spray for Dry Eye Disease. Completed, enrolled 53 participants across 2 sites.

Detailed Summary

The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 16, 2018
Enrollment StartAug 14, 2018
Primary CompletionSep 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.9 years ago

Interventions

OC-02 (simpinicline) nasal spraydrug

OC-02 (simpinicline) nasal spray, 11.1 mg/ml

Placebo (vehicle) nasal spraydrug

Placebo (vehicle) nasal spray